ReviewMedical oncology (Northwood, London, England)2026
A different perspective on the cancer stem cell theory.
Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased recurrence risk, aggressiveness, metastasis, and poor prognosis of cancer disease are challenges of conventional cancer treatment strategies attributed to cancer stem cells (CSCs). These cells are primarily defined as a small number of cancer cells with stemness potency. They are known to be the potential cause of conventional anticancer therapy resistance, including chemo-radiotherapy or hormonal reagents that can self-renew, remain dormant for an extended period, and, in doing so, promote tumor growth. CSC's theory presents possible causes of disease relapse after successful conventional therapies. Removing these stem cells seems logical to optimize the outcomes of related therapeutic strategies. Comprehensively identifying the evolutionary path and biology of cancer cells and supposed CSCs can direct us towards appropriate management of the disease. In the current study, we discuss recent findings that present clues to reshape our understanding of cancer stem cell theory and portray a novel perspective on cancer cell evolution and potential cancer stem cells (CSCs). Although there is a need for more in-depth studies in this area, current theory can alter therapeutic options and disease control methods. It may lead to a revolution in oncology science.
Indexed as
Identifiers
41781591What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.